Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectrum Pharmaceuticals, a commercial-stage biotechnology company, has reported total revenues of $8.6m for the fourth quarter ended December 31, 2009, compared to $8.04m for the same period in 2008.
Subscribe to our email newsletter
Spectrum Pharmaceuticals posted a net income attributable to stockholders of $10.18m, or $0.20 per diluted share, compared to net loss of $8.87m, or $0.28 per diluted share, for the prior year period. Loss from operations was $9.29m, compared to $11.8m for the same quarter in 2008.
For the fiscal year ended December 31, 2009, the company has posted a net loss attributable to stockholders of $19.04m, or $0.48 per diluted share, compared to $14.19m, or $0.45 per diluted share, for the year ago period.
Total revenue was $38.02m for the 12 months, compared to $28.72m for the year ago period. Loss from operations was $28.5m, compared to $19.16m for the year ago period.
Rajesh Shrotriya, chairman and CEO, said: “The year 2009 was filled with notable accomplishments for Spectrum that have laid the groundwork for continued and significant growth in 2010 and beyond.
“We currently expect to file the New Drug Applications for Belinostat and apaziquone in 2011 and 2012, respectively. We have been successful in growing Spectrum through strict fiscal discipline, portfolio management, and an opportunistic approach to drug acquisitions.”